Skip to content

Metacognitive structure and its metabolomic profile in patients with depressive disorders

Metacognitive structure and its metabolomic profile in patients with depressive disorders

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091242
Enrollment
Unknown
Registered
2024-10-23
Start date
2024-04-15
Completion date
Unknown
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depressive disorder

Interventions

depression group:Scale assessment and blood samples
control group:Scale assessment and blood samples

Sponsors

Hangzhou Seventh People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Meet the International Classification of Diseases ICD-10 criteria for the diagnosis of depressive disorders; (2) Outpatients or inpatients, aged 18-60 years; (3) Have been treated with antidepressant medication only, and have not been treated with a combination of mood stabilizers or antipsychotic medication; (4) Have at least elementary school education and be able to cooperate in completing cognitive function tests and clinical assessments; (5) No history of serious substantial organ as well as metabolic abnormalities or endocrine diseases; (6) A total HAMD-17 score of 17-24 at baseline at the time of enrollment; (7) The consent of the patients and their families should be obtained and an informed consent form should be signed.

Exclusion criteria

Exclusion criteria: (1) Pregnant or lactating women; (2) Patients with depressive disorders accompanied by psychotic symptoms, patients with suicidal tendencies; (3) Patients with severe physical illnesses, such as severe liver or kidney disease, heart disease, hypertension, diabetes, thyroid disease, etc. (4) A history of psychoactive substance abuse or taking any medication that may affect cognitive function (e.g., glucocorticoids, beta-blockers, opioid analgesics, and central stimulants).

Design outcomes

Primary

MeasureTime frame
metacognition;Glutamic acid;aspartic acid;glutamine;N-acetylaspartic acid;glycine;gamma-aminobutyric acid;tryptophan;histidine;tyrosine;phenylalanine;deoxycholic acid;valine;alanine;proline;argnine;leucine ;isoleucine;creatine;fleshiness;palmitoleic acid;asparagine;

Secondary

MeasureTime frame
HAMD-17 Depression Scale;

Countries

China

Contacts

Public ContactMing Tao

Zhejiang University of Chinese Medicine

taoming@21cn.com+86 138 6807 2111

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026